CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
InProTher is developing an innovative immunotherapy called BreakImmune, which targets human endogenous retroviruses to treat various cancers. By engineering specific antigens, this approach aims to activate the immune system to effectively destroy tumor cells, with the first product being a vaccine for solid tumors com…
InProTher (IPT) is developing a unique immunotherapy BreakImmune that effectively targets endogenous retroviruses (HERVs) to treat cancer. HERVs are not expressed in normal tissues, but are expressed in several major cancers, such as breast (88%), prostate (90%), ovarian (90%), and pancreatic (80%).
Thus, HERVs can be a potential target for the immune system to destroy tumor cells. IPT technology relies on the engineering of HERVK antigens to be used as effective cancer vaccines.
The administr…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
